ALFA Finder
| Market Cap | ₹6,070.74 CrMid Cap |
|---|---|
| Revenue TTM | ₹2,523.63 CrOperating |
| Piotroski Score | 8High Health |
| 1-Yr Return | 77.16%Performance |
Key highlights
- Received REACH registration from the European Chemicals Agency (ECHA) for Triacetin
- Certification enables the company to legally export Triacetin to all EU countries
- Strengthens global regulatory compliance and expansion into international markets
- Company reported a 37.08% YoY growth in quarterly operating revenue to ₹756.26 crore
- Triacetin is a versatile specialty chemical used in pharmaceuticals and food industries
What Approval Was Received?
IOL Chemicals and Pharmaceuticals Limited has successfully obtained REACH registration for Triacetin from the European Chemicals Agency (ECHA). This certification, granted under the Registration, Evaluation, Authorisation and Restriction of Chemicals framework, signifies that the product meets the stringent safety and environmental standards required for the European market. The scope of this approval extends to all member nations of the European Union, removing a significant regulatory barrier for the company’s specialty chemicals division.
This registration is a critical prerequisite for any chemical manufacturer intending to sell or distribute substances in quantities of one tonne or more per year within the EU.
Why This Approval Matters
- Unlocks access to the vast European market for Triacetin exports
- Triacetin serves diverse industries including cigarette filters, food additives, and pharmaceuticals
- Enhances the company's competitive positioning against global chemical manufacturers
- Ensures long-term regulatory sustainability for the product line in international territories
- Validates the company's manufacturing and safety protocols under European standards
Business Overview
IOL Chemicals and Pharmaceuticals is a significant player in the global pharmaceutical and specialty chemicals sector. The company holds a dominant position as one of the largest producers of Ibuprofen globally, with a fully integrated manufacturing facility located in Barnala, Punjab. Beyond active pharmaceutical ingredients, the company has been aggressively diversifying its portfolio into specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, and now Triacetin.
This diversification strategy aims to reduce dependence on its core API business while leveraging its existing chemical manufacturing expertise. The company's focus on high-growth global markets is reflected in its recent efforts to secure international registrations and certifications.
Financial Context
- Net profit for the June 2026 quarter increased by 89.8% YoY to reach ₹64.4 crore
- Promoter holding remains stable and high at 62.28% as of the latest quarter
- TTM Price-to-Earnings ratio stands at 36.11x compared to the industry average of 47.65x
- The company maintains a high Durability Score of 85
- Exports contribute a significant portion of the total revenue, supported by global compliance
| Share price | ₹206.82 |
|---|---|
| Market capitalisation | ₹6,070.74 Cr |
| Revenue (annual) | ₹2,319.06 Cr |
| Net profit (annual) | ₹137.64 Cr |
| Revenue (latest quarter) | ₹756.26 Cr+22.09% vs previous quarter |
| Net profit (latest quarter) | ₹64.40 Cr+21.14% vs previous quarter |
| P/E (TTM) | 36.11×Sector 50.06× |
| Promoter holding | 62.28%+4.80% QoQ |
| FII holding | 4.87%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by IOL Chemicals and Pharmaceuticals Limited announcing the receipt of EU-REACH registration for Triacetin. Market figures from a third-party data provider.
